Comparative effectiveness and safety of apixaban and vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation treated in routine German practice
CI Coleman, WF Peacock, M Antz - Heart, Lung and Circulation, 2018 - Elsevier
Background Scarce data comparing real-world outcomes between apixaban and vitamin K
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to
assess the effectiveness and safety of newly-initiated apixaban vs. VKA in German NVAF
patients. Materials and Methods We performed a retrospective analysis in German
outpatients using IMS Disease Analyzer data. Adults newly-initiated on apixaban or a VKA
from January 2013 to March 2015 with a diagnosis of NVAF on the day of the first qualifying …
antagonist (VKA) users with nonvalvular atrial fibrillation (NVAF) are available. We sought to
assess the effectiveness and safety of newly-initiated apixaban vs. VKA in German NVAF
patients. Materials and Methods We performed a retrospective analysis in German
outpatients using IMS Disease Analyzer data. Adults newly-initiated on apixaban or a VKA
from January 2013 to March 2015 with a diagnosis of NVAF on the day of the first qualifying …
以上显示的是最相近的搜索结果。 查看全部搜索结果